Comparative Pharmacology
Head-to-head clinical analysis: GOPRELTO versus ZTLIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GOPRELTO versus ZTLIDO.
GOPRELTO vs ZTLIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical analgesic; produces local anesthesia by reversibly blocking sodium channels in nerve cell membranes, inhibiting nerve impulse conduction.
ZTLIDO (lidocaine) is a sodium channel blocker that binds to voltage-gated sodium channels in neuronal membranes, stabilizing the membrane and inhibiting the initiation and conduction of nerve impulses, thereby producing local anesthesia.
100 mcg (0.1 mg) administered as a single intra-articular injection per affected joint. Maximum total dose per treatment session is 4 mL (4 mg).
1.8% lidocaine topical patch: Apply up to 3 patches at once to intact skin for up to 12 hours in a 24-hour period.
None Documented
None Documented
Terminal elimination half-life is 2.5 hours in patients with normal renal function. Clinical context: In moderate renal impairment (CrCl 30-40 mL/min), half-life is prolonged to 3.2 hours; in severe impairment, up to 6 hours.
Terminal elimination half-life is 1.5 to 2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours with CrCl <30 mL/min).
Primarily renal elimination: 70% as unchanged drug, 15% as metabolites. Biliary/fecal excretion accounts for approximately 10%.
Primarily renal excretion as unchanged drug (80-85%) and metabolites (10-15%); less than 5% excreted in feces.
Category C
Category C
Topical Anesthetic
Topical Anesthetic